Just Healthcare

Just Healthcare

Share this post

Just Healthcare
Just Healthcare
New ADHD Treatment Centanafadine Shows Promising Results in Adults

New ADHD Treatment Centanafadine Shows Promising Results in Adults

Centanafadine, a novel triple reuptake inhibitor, demonstrates clinically significant improvement in adult ADHD symptoms.

Naveen Sankar S's avatar
Naveen Sankar S
Aug 02, 2025
∙ Paid

Share this post

Just Healthcare
Just Healthcare
New ADHD Treatment Centanafadine Shows Promising Results in Adults
Share
Generated image

A recent combined analysis of two phase 3 clinical trials has found that centanafadine, a unique norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), significantly reduces symptoms in adults with attention-deficit/hyperactivity disorder (ADHD). Centanafadine notably improved both hyperactivity/impulsivity and inattention symptoms within s…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Just Healthcare
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share